PMID- 36626493
OWN - NLM
STAT- MEDLINE
DCOM- 20230112
LR  - 20230113
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 49
DP  - 2022 Dec 9
TI  - The effects of curcumin supplementation on high-sensitivity C-reactive protein, 
      serum adiponectin, and lipid profile in patients with type 2 diabetes: A protocol 
      for systematic review and meta-analysis.
PG  - e31942
LID - 10.1097/MD.0000000000031942 [doi]
LID - e31942
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is an ensemble of metabolic diseases 
      that has reached pandemic dimensions all over the world. There is a lack of 
      evidence on the contribution of curcumin in the treatment of T2DM. We conducted a 
      protocol for systematic review and meta-analysis to evaluate whether curcumin 
      supplementation is effective and safe in T2DM patients. METHODS: The systematic 
      review will follow the guidelines of Preferred Reporting Items for Systematic 
      Reviews and Meta-analyses Protocols (PRISMA-P). We will obtain studies through 
      PubMed, Cochrane Library, Embase, Web of Science, and Medline databases. In 
      addition, we will also collect 4 databases of China: China National Knowledge 
      Infrastructure, China Biomedical Literature Database, China Science Journal 
      Database, and Wan-fang Database. Eligible study conference abstracts and 
      reference lists of manuscripts will be searched. The data collection and analysis 
      will be conducted independently by 2 reviewers. Meta-analysis will be performed 
      using Review Manager software, version 5.3 (Update Software Ltd, Oxford, Oxon, 
      UK). RESULTS: The results of this systematic review and meta-analysis will be 
      published in a peer-reviewed journal. CONCLUSION: The findings of this systematic 
      review may encourage supplementation of curcumin and its preparation specifically 
      in T2DM patients. Nevertheless, the application of curcumin supplementation in 
      clinical practice should be taken with individual's contributing factors.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Li, Jie
AU  - Li J
AD  - Department of Clinical Laboratory, First People's Hospital of Tianshui, Gansu, 
      China.
FAU - Sun, Lifang
AU  - Sun L
AUID- ORCID: 0000-0003-2481-6445
AD  - Department of Blood Transfusion, First People's Hospital of Tianshui, Gansu, 
      China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - IT942ZTH98 (Curcumin)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 0 (Adiponectin)
RN  - 0 (Lipids)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Curcumin/therapeutic use
MH  - C-Reactive Protein
MH  - Adiponectin
MH  - Systematic Reviews as Topic
MH  - Meta-Analysis as Topic
MH  - Lipids
MH  - Dietary Supplements
MH  - Research Design
PMC - PMC9750569
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2023/01/11 06:00
MHDA- 2023/01/13 06:00
PMCR- 2022/12/09
CRDT- 2023/01/10 13:35
PHST- 2023/01/10 13:35 [entrez]
PHST- 2023/01/11 06:00 [pubmed]
PHST- 2023/01/13 06:00 [medline]
PHST- 2022/12/09 00:00 [pmc-release]
AID - 00005792-202212090-00007 [pii]
AID - 10.1097/MD.0000000000031942 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Dec 9;101(49):e31942. doi: 
      10.1097/MD.0000000000031942.